{"id":"W4379979648","doi":"10.1002/hon.3164_263","title":"An open‐label phase 1/2 study of favezelimab plus pembrolizumab in patients with relapsed/refractory classical Hodgkin lymphoma with/without previous anti‐PD‐1 treatment","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Manitoba; CancerCare Manitoba; Jewish General Hospital","funders":"Gilead Sciences","keywords":"Medicine; Pembrolizumab; Refractory (planetary science); Cohort; Internal medicine; Lymphoma; Oncology; Gastroenterology; Cancer; Surgery; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002255859,0.002135796,0.003317113,0.0006180148,0.0006608092,0.001337641,0.001064844,0.001378068,0.005371587],"category_scores_gemma":[0.001255133,0.001121614,0.001923209,0.000489351,0.001354571,0.001458448,0.0004330484,0.003368439,0.001287065],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001368303,"about_ca_system_score_gemma":0.001950992,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001318746,"about_ca_topic_score_gemma":0.003174026,"domain_scores_codex":[0.9993087,0.0003083507,0.00003264689,0.0001449823,0.00006350961,0.0001418318],"domain_scores_gemma":[0.9991616,0.0001295733,0.0001302353,0.00009394635,0.00006583302,0.0004188878],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8654233,0.08493657,0.003401128,0.0005448188,0.00121251,0.0001470089,0.0001887986,0.0007805714,0.01470744,0.0001242547,0.00145565,0.0270781],"study_design_scores_gemma":[0.7059929,0.2846754,0.00595412,0.00001904464,0.0004339976,0.0001009719,0.00004415631,0.0004042713,0.0007880779,0.0001109135,0.001453404,0.00002274056],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9897481,0.001852491,0.0005111055,0.0004116677,0.0002830678,0.004573106,0.001141444,0.00007490056,0.001404175],"genre_scores_gemma":[0.9849983,0.001636163,0.001784487,0.0008611357,0.0004261118,0.006078429,0.001828651,0.00002959851,0.002357151],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005371587,"threshold_uncertainty_score":0.01796979,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05988519933506927,"score_gpt":0.378718182469252,"score_spread":0.3188329831341827,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}